Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by CytRx Corporation CytRx Corporation Relaunches as LadRx Corporation September 23, 2022 From CytRx Corporation Via Business Wire Tickers CYTR European Patent Office Awards CytRx Key Patent September 07, 2022 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors August 09, 2022 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock May 19, 2022 From CYTRX CORPORATION Via Business Wire Tickers CYTR CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc. May 17, 2022 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Partners with Oncology Development Expert to Advance LADR Platform April 20, 2022 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress March 21, 2022 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C February 24, 2022 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C February 14, 2022 From CytRx Corporation Via Business Wire Tickers CYTR CytRx to Hold Town Hall for Stockholders on Thursday, January 20th January 18, 2022 From CytRx Corporation Via Business Wire Tickers CYTR CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference January 07, 2022 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer January 03, 2022 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer December 21, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada November 30, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Comments on Quarterly Results and Recent Strategic Initiatives November 12, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada November 09, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C November 02, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment October 14, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx to Present at Upcoming Virtual LD Micro Conference October 05, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 08, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C August 24, 2021 From CytRx Corporation Via Business Wire Tickers CYTR ORPH CytRx Comments on Quarterly Results and Recent Strategic Initiatives August 12, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders July 29, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022 July 29, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor July 16, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor July 13, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C June 30, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C June 18, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx to Present at Upcoming Investor Conferences June 02, 2021 From CytRx Corporation Via Business Wire Tickers CYTR CytRx Comments on Quarterly Results and Year-to-Date Progress May 13, 2021 From CytRx Corporation Via Business Wire Tickers CYTR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.